Biosimilar for remicade?

Yes. Remicade (infliximab) has several biosimilars available in different regions. The main infliximab biosimilars you might see include:

- Inflectra (infliximab-dyyb) — one of the first infliximab biosimilars approved in the US.
- Renflexis (infliximab-abda) — another US-approved infliximab biosimilar.
- Ixifi (infliximab-qbtx) — US-approved.
- Flixabi (infliximab) — available in Europe and other markets (not all countries have it).
- Remsima (infliximab-axxq) — widely used in many regions (often marketed as a Remsima/Inflectra variant depending on country).

Availability and naming can vary by country. Interchangeability (the ability for a pharmacist to substitute a biosimilar for Remicade without a prescriber’s approval) is country-specific and may apply to only certain products in some places.

If you tell me your country and the condition you’re treating (e.g., Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis), I can list the exact approved infliximab biosimilars for you and any dosing/monitoring notes.